Who is sponsoring NCT01024036?

NCT01024036 is sponsored by Janssen Research & Development, LLC.

What condition does NCT01024036 study?

NCT01024036 studies Multicentric Castleman's Disease.

What drugs are being tested in NCT01024036?

Interventions: Siltuximab, Placebo, Best Supportive Care (BSC).

What is the status of NCT01024036?

NCT01024036 is currently COMPLETED.

Last reviewed 2018-03-21 · How we verify

A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease

NCT01024036 PHASE2 COMPLETED Results posted

The purpose of this study is to demonstrate that CNTO 328 when administered in combination with best supportive care (BSC) is superior to BSC in terms of durable tumor and symptomatic response (complete response or partial response) among patients with Multicentric Castleman's Disease.

Details

Lead sponsor	Janssen Research & Development, LLC
Phase	PHASE2
Status	COMPLETED
Enrolment	79
Start date	Thu Mar 18 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Feb 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Multicentric Castleman's Disease

Interventions

Siltuximab
Placebo
Best Supportive Care (BSC)

Countries

Hong Kong, Malaysia, Taiwan, South Korea, New Zealand, Netherlands, Russia, Belgium, United States, France, Israel, Hungary, Norway, Canada, Brazil, Spain, United Kingdom, Germany, Australia, China, Singapore, Egypt, India